Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    02392078
Previous Study | Return to List | Next Study

Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02392078
Recruitment Status : Recruiting
First Posted : March 18, 2015
Last Update Posted : October 10, 2019
Sponsor:
Information provided by (Responsible Party):
Monteris Medical

Brief Summary:
The NeuroBlate® System (NBS) is a minimally invasive robotic laser thermotherapy tool that is being manufactured by Monteris Medical. Since it received FDA clearance in May 2009, the NBS has been used in over 2000 procedures conducted at over 56 leading institutions across United States. This is a prospective, multi-center registry that will include data collection up to 12 months to evaluate procedural success, local control failure rate, and QoL in up to 1,000 patients and up to 50 sites.

Condition or disease Intervention/treatment
Metastatic Brain Tumor Primary Brain Tumor Epileptic/Seizure Foci Device: NeuroBlate System

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN) Prospective Registry
Study Start Date : October 2015
Estimated Primary Completion Date : June 2020
Estimated Study Completion Date : September 2020

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Procedural Success [ Time Frame: up to 12 months ]
  2. Local control Failure Rate [ Time Frame: up to 12 months ]
  3. Change in Quality of Life [ Time Frame: up to 12 months ]
    Assessed by KPS (CNS malignancy patients; through 24 months), EQ5D (all patients; through 12 months), FACT-Br (CNS malignancy patients; through 12 months), and Qolie-31 (patients with seizure foci; through 12 months).


Secondary Outcome Measures :
  1. Safety (Reportable adverse events) [ Time Frame: up to 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients who preferred management for soft tissue through interstitial irradiation or thermal therapy by the NeuroBlate® System, in the opinion of the treating physician
Criteria

Inclusion Criteria:

  1. Patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements
  2. Patient who is to undergo thermal therapy by the NeuroBlate® System for treatment of their neurological disorder

Exclusion Criteria:

  1. Patient who is, or is expected to be inaccessible for follow-up
  2. Patient meets any exclusion criteria required by local law (e.g. age)
  3. Other concurrent medical or other condition (chronic or acute in nature) that in the opinion of the investigator may prevent participation or otherwise render patient ineligibility for the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02392078


Contacts
Layout table for location contacts
Contact: Nissa Mollema 763-253-4710 nmollema@monteris.com
Contact: Beth Larson-DeBruzzi 763-253-4710 ext 2724 bldebruzzi@monteris.com

Locations
Layout table for location information
United States, Arizona
Barrow Neurological Institute at Dignity Health St. Joseph's Hospital & Medical Center Recruiting
Phoenix, Arizona, United States, 85013
Contact: Odilette Trevizo, RN, CNRN    602-406-1463    Odilette.Trevizo@DignityHealth.org   
Principal Investigator: Kris Smith, MD         
United States, California
University of California, San Diego Recruiting
La Jolla, California, United States, 92093
Contact: Lara Rose    858-822-6575    ljrose@ucsd.edu   
Principal Investigator: David Piccioni, MD         
United States, Connecticut
Yale University School of Medicine Recruiting
New Haven, Connecticut, United States, 06510
Contact: Judith Hess    203-737-6259    judith.hess@yale.edu   
Principal Investigator: Veronica Chiang, MD         
United States, Florida
Advent Health Orlando Recruiting
Orlando, Florida, United States, 32804
Contact: Brooke Hartwell    773-316-1514    Brooke.Hartwell@AdventHealth.com   
Principal Investigator: James Baumgartner, MD         
United States, Kansas
University of Kansas Medical Center Recruiting
Kansas City, Kansas, United States, 66160
Contact: Lindsay Richardson    913-574-0412    lrichardson5@kumc.edu   
Contact: Catherine Lauridsen    913-588-4573    clauridsen2@kumc.edu   
Principal Investigator: Patrick Landazuri, MD         
United States, Kentucky
University of Louisville Recruiting
Louisville, Kentucky, United States, 40208
Contact: Anna Williford    502-852-7402    anna.williford@louisville.edu   
Principal Investigator: Joseph Neimat, MD         
Norton Cancer Institute Recruiting
Louisville, Kentucky, United States, 40241
Contact: Debbie Ritchey    502-446-8544    debbie.ritchey@nortonhealthcare.org   
Principal Investigator: David Sun, MD         
United States, Minnesota
University of Minnesota Recruiting
Minneapolis, Minnesota, United States, 55455
Contact: Clark Chen       ccchen@umn.edu   
Principal Investigator: Clark Chen, MD         
United Children's Hospital St. Paul Recruiting
Saint Paul, Minnesota, United States, 55102
Contact: Katherine Ingram    612-813-6329    Katherine.Ingram@childrensmn.org   
Principal Investigator: Jospeh Petronio, MD         
United States, Missouri
Washington University Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Jeanine Portell    314-362-2940    jportell@wustl.edu   
Principal Investigator: Albert Kim, MD         
United States, New York
New York University Langone Medical Center Recruiting
New York, New York, United States, 10016
Contact: Malcolm Delara    212-263-4414    malcolm.delara@nyulangone.org   
Contact: Ankeeta Joshi    212-263-4431    ankeeta.joshi@nyumc.org   
Principal Investigator: Sylvia Kurz, MD         
Ichan School of Medicine at Mount Sinai Recruiting
New York, New York, United States, 10029
Contact: Ryan Adams    212-241-8349    Ryan.Adams@mountsinai.org   
Principal Investigator: Constantino Hadjipanayis, MD         
Weill Cornell Medicine Withdrawn
New York, New York, United States, 10065
SUNY Upstate Medical University Recruiting
Syracuse, New York, United States, 13210
Contact: Sean Huckins    315-464-8477    huckinss@upstate.edu   
Principal Investigator: Zulma Tovar-Spinoza, MD         
United States, North Carolina
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27710
Contact: Tammy O'Brien    919-660-9329    tammy.obrien@duke.edu   
Principal Investigator: Peter Fecci, MD         
Wake Forest Recruiting
Winston-Salem, North Carolina, United States, 27157
Contact: Wendy Jenkins    336-716-3842    wejenkin@wakehealth.edu   
Principal Investigator: Stephen Tatter, MD         
United States, Ohio
University Hospitals Cleveland Medical Center Recruiting
Cleveland, Ohio, United States, 44106
Contact: Karen Devine    213-368-0076    karen.devine@uhhospitals.org   
Principal Investigator: Andrew Sloan, MD         
Cleveland Clinic Foundation Recruiting
Cleveland, Ohio, United States, 44195
Contact: Teresa Allison    216-444-6459    ALLISOT@ccf.org   
Principal Investigator: Alireza Mohammadi, MD         
United States, Pennsylvania
Thomas Jefferson University Recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: Jaime Dougherty    215-955-7962    Jaime.Dougherty@jefferson.edu   
Principal Investigator: Kevin Judy, MD         
University of Pittsburgh Medical Center Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Madison Remick    216-407-1651    mar355@pitt.edu   
Principal Investigator: Taylor Abel, MD         
United States, Texas
MD Anderson Recruiting
Houston, Texas, United States, 77030
Contact: Carmen Jacobs    713-745-3246    cjacobs@mdanderson.org   
Principal Investigator: Ganesh Rao, MD         
Canada, British Columbia
University of British Columbia Completed
Vancouver, British Columbia, Canada, V5Z 1M9
Sponsors and Collaborators
Monteris Medical
Investigators
Layout table for investigator information
Principal Investigator: Eric Leuthardt, MD Washington University School of Medicine

Layout table for additonal information
Responsible Party: Monteris Medical
ClinicalTrials.gov Identifier: NCT02392078     History of Changes
Other Study ID Numbers: LAANTERN
First Posted: March 18, 2015    Key Record Dates
Last Update Posted: October 10, 2019
Last Verified: October 2019
Keywords provided by Monteris Medical:
Procedural Success
Progression
Quality of Life
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Neoplasms
Seizures
Neoplasms
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Brain Diseases
Central Nervous System Diseases